NMN Study: Safety Evaluation of Oral Administration of β-Nicotinamide Mononucleotide in Healthy Adult Men and Women.
Summary of Results:
Oral administration of β-NMN did not produce changes beyond normal physiological variations in various clinical assessments, including anthropometric, hematological, biochemical, urine, and body composition analyses. Furthermore, no serious adverse events were reported throughout the study period. Our results suggest that β-NMN is safe and well-tolerated by healthy adult men and women at a daily oral dose of 1250 mg over a period of up to four weeks.
Research Summary:
Declining levels of intracellular nicotinamide adenine dinucleotide (NAD+), an essential coenzyme for metabolic activity, are associated with various age-related diseases and metabolic abnormalities. Research both in vivo and in vitro has demonstrated that increasing NAD+ levels in cells or tissues by supplementing with nicotinamide mononucleotide (NMN), a precursor of NAD+, can alleviate age-related conditions and metabolic disorders. While several clinical trials have been conducted in recent years to investigate the efficacy of NMN in humans, there is still limited information on the safety of long-term daily oral administration of ≥ 1000 mg NMN in healthy adult men and women.
Therefore, we conducted a randomized, double-blind, placebo-controlled study to assess the safety of daily oral administration of 1250 mg β-nicotinamide mononucleotide (β-NMN) for up to 4 weeks in 31 healthy adult men and women aged 20 to 65 years. During the study period, various clinical parameters were analyzed, including anthropometry, hematology, biochemistry, urine, and body composition. Additionally, hormone levels, NAD+ levels, and immunological markers were examined. The study was conducted as a randomized, double-blind, placebo-controlled parallel-group trial.
The results showed that the oral administration of 1250 mg β-NMN for 4 weeks was well-tolerated by all participants. No significant adverse effects were observed, and there were no issues with laboratory values or subjective symptoms in those who completed the study. Furthermore, favorable changes were observed in various biomarkers, such as NAD+ and certain hormones. These findings suggest that β-NMN is safe for daily oral administration in healthy adults and may be beneficial for regulating age-related muscle dysfunction.
Source: https://pubmed.ncbi.nlm.nih.gov/36002548/
